| Market Capitalization (Millions $) |
1,160 |
| Shares
Outstanding (Millions) |
92 |
| Employees |
37 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-54 |
| Cash Flow (TTM) (Millions $) |
25 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of innovative immuno-oncology therapies. The company is known for its expertise in the field of immunotherapy and aims to transform the treatment of cancer by harnessing the body's immune system to fight the disease.
Corvus Pharmaceuticals has a diverse pipeline of drug candidates, with a particular focus on targeting the adenosine-cancer axis. Adenosine is a molecule that suppresses the immune response and is commonly found in the tumor microenvironment. By targeting this pathway, the company intends to enhance the immune system's ability to effectively eliminate cancer cells.
The company's lead drug candidate, CPI-006, is an antagonist antibody that is being developed for various cancer indications. CPI-006 has shown promising results in preclinical and early clinical studies, and Corvus Pharmaceuticals is currently advancing it through various clinical trials.
Overall, Corvus Pharmaceuticals Inc is dedicated to the development of novel immuno-oncology therapies that can improve the lives of patients with cancer. Through its innovative approach, the company aims to address unmet medical needs and improve treatment outcomes in oncology.
Company Address: 901 Gateway Boulevard, Third Floor South San Francisco 94080 CA
Company Phone Number: 900-4520 Stock Exchange / Ticker: NASDAQ CRVS
|
2.66% 